



Alessandro Mazzocca

Date of birth: 15/09/1990 | **Nationality:** Italian | **Gender:** Male | (+39) 3333221315 |

a.mazzocca@unicampus.it | Via Alvaro del Portillo 200, 00145, Roma, Italy

WORK EXPERIENCE

19/10/2016 – CURRENT

MD – UNIVERSITY CAMPUS BIO-MEDICO, DEPARTMENT OF MEDICAL ONCOLOGY

Via Alvaro del Portillo 200, 00128, Rome, Italy

29/12/2018 – CURRENT – Rome, Italy

RECIDENCY (MEDICAL ONCOLOGY)

Clinical trials activity

2019-present Sub-P.I.	VOYAGER phase III trial	Avapritinib in advanced GIST
2019-present Sub-P.I.	SEAL phase III trial	Selinexor in advanced DDLPS
2019-present Sub-P.I.	DeFi phase III trial	Nirogacestat in desmoid tumors
2020-present Sub-P.I.	TOMAS-2 phase II trial	Trabectedin+Olaparib in soft tissue sarcomas
2020-present Sub-P.I.	APROMISS phase III trial	Anlotinib in ASPS/LMS/SS
2020-present Sub-P.I.	INTRIGUE phase III trial	Ripretinib in advanced GIST
2020-present Sub-P.I.	METROPHOLYS phase III trial	Doxo vs Cyclo in elderly patients with STS
2021-present Sub-P.I.	STRASS-2 phase III trial	Neoadjuvant chemotherapy in retroperitoneal sarcomas

Invited Speeches

2019	(Italian)	Approccio multidisciplinare ai sarcomi dei tessuti molli: focus sull'Oncologia Medica Università Campus Bio-Medico, Rome, Italy
2019	(Italian)	La gestione multidisciplinare dei sarcomi dei tessuti molli Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
2021	(Italian)	COMU: Sintetizza e commenta Chicago 2021. Sarcomi e Tumori neuroendocrini Virtual Meeting

EDUCATION AND TRAINING

2005 – 2009 – Sapri (SA), Italy

HIGH SCHOOL DEGREE IN JULY 2009 WITH 100/100 – "Galileo Galilei"

2010 – 2016 – Rome, Italy

DEGREE IN MEDICINE AND SURGERY – University Cattolica del Sacro Cuore

110/110 cum laude | KRAS as prognostic factor in metastatic colorectal cancer

29/12/2017 – CURRENT – Rome, Italy

SCHOOL OF MEDICAL ONCOLOGY – University Campus Bio-Medico

Area of Interest

Rare Cancers
Clinical trial activity

in particular soft tissue sarcomas and GIST

● LANGUAGE SKILLS

Mother tongue(s): ITALIAN

Other language(s):

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken production	Spoken interaction	
ENGLISH	C1	C2	C1	B2	C1

Levels: A1 and A2: Basic user; B1 and B2: Independent user; C1 and C2: Proficient user

● PUBLICATIONS

New frontiers in the medical management of gastrointestinal stromal tumours

Therapeutic Advances in Medical Oncology
<https://doi.org/10.1177/1758835919841946> - 2019

Italian survey of second tumors in patients with diagnosis of GIST (gastrointestinal stromal tumor)

Journal of Clinical Oncology
https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.11032 - 2019

Use of cardioprotective dexrazoxane and myelotoxicity in anthracycline-treated soft tissue sarcoma patients

Chemotherapy
<https://doi.org/10.1159/000501195>

Update of NGS analysis of Italian survey of second tumors in patients with diagnosis of GIST (gastrointestinal stromal tumor)..

Journal of Clinical Oncology
https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.e23518 - 2020

Recent Advances in Desmoid Tumor Therapy. Cancers.

Cancers
<https://doi.org/10.3390/cancers12082135> - 2020

Selinexor, a First in Class, Nuclear Export Inhibitor for the Treatment of Advanced Malignant Peripheral Nerve Sheath Tumor

The Oncologist
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018316/> - 2021

The prognostic significance of lactate dehydrogenase levels in seminoma patients with advanced disease: an analysis by the Global Germ Cell Tumor Collaborative Group (G3).

World Journal of Urology
<https://link.springer.com/article/10.1007/s00345-021-03635-3> - 2021

Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors (GIST): A retrospective, multicenter, real-world study

Journal of Clinical Oncology
https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.e23521 - 2021